Cronos Group Inc. (NASDAQ: CRON) Stock Competitors & Peer Comparison
See CRON's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CRON and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CRON | $3.17 | +2.92% | 1.2B | 30.10 | $0.11 | N/A |
| TAK | $17.41 | -0.40% | 55.4B | 12.52 | $1.39 | +3.62% |
| HLN | $9.80 | -1.36% | 43.2B | 18.28 | $0.54 | +1.80% |
| TEVA | $36.74 | +0.71% | 42.8B | 12.54 | $2.93 | N/A |
| VTRS | $16.10 | -1.11% | 18.7B | 6.39 | $2.52 | +2.98% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.13 | -2.64% | 11.1B | 20.91 | $1.06 | N/A |
| RDY | $12.39 | -0.48% | 10.3B | 20.30 | $0.61 | +0.67% |
| LNTH | $100.73 | +0.05% | 6.6B | 16.93 | $5.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
CRON vs TAK Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, TAK has a market cap of 55.4B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while TAK trades at $17.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas TAK's P/E ratio is 12.52. In terms of profitability, CRON's ROE is +0.06%, compared to TAK's ROE of +0.02%. Regarding short-term risk, CRON is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for CRON.Check TAK's competition here
Haleon plc (NYSE: HLN)
CRON vs HLN Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, HLN has a market cap of 43.2B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while HLN trades at $9.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas HLN's P/E ratio is 18.28. In terms of profitability, CRON's ROE is +0.06%, compared to HLN's ROE of +0.17%. Regarding short-term risk, CRON is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for CRON.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
CRON vs TEVA Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, TEVA has a market cap of 42.8B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while TEVA trades at $36.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas TEVA's P/E ratio is 12.54. In terms of profitability, CRON's ROE is +0.06%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, CRON is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for CRON.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
CRON vs VTRS Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, VTRS has a market cap of 18.7B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while VTRS trades at $16.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas VTRS's P/E ratio is 6.39. In terms of profitability, CRON's ROE is +0.06%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, CRON is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for CRON.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
CRON vs ITCI Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas ITCI's P/E ratio is -180.64. In terms of profitability, CRON's ROE is +0.06%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, CRON is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for CRON.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
CRON vs CTLT Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas CTLT's P/E ratio is -27.84. In terms of profitability, CRON's ROE is +0.06%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, CRON is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for CRON.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
CRON vs ELAN Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, ELAN has a market cap of 11.1B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while ELAN trades at $22.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas ELAN's P/E ratio is 20.91. In terms of profitability, CRON's ROE is +0.06%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, CRON is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for CRON.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
CRON vs RDY Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, RDY has a market cap of 10.3B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while RDY trades at $12.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas RDY's P/E ratio is 20.30. In terms of profitability, CRON's ROE is +0.06%, compared to RDY's ROE of +0.09%. Regarding short-term risk, CRON is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for CRON.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
CRON vs LNTH Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while LNTH trades at $100.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas LNTH's P/E ratio is 16.93. In terms of profitability, CRON's ROE is +0.06%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, CRON is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for CRON.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
CRON vs AMRX Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while AMRX trades at $17.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas AMRX's P/E ratio is 19.62. In terms of profitability, CRON's ROE is +0.06%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, CRON is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for CRON.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
CRON vs INDV Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while INDV trades at $38.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas INDV's P/E ratio is 10.61. In terms of profitability, CRON's ROE is +0.06%, compared to INDV's ROE of -2.16%. Regarding short-term risk, CRON is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for CRON.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
CRON vs SUPN Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while SUPN trades at $47.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas SUPN's P/E ratio is 15.64. In terms of profitability, CRON's ROE is +0.06%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, CRON is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for CRON.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
CRON vs RGC Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, RGC has a market cap of 2.5B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while RGC trades at $5.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas RGC's P/E ratio is -356.34. In terms of profitability, CRON's ROE is +0.06%, compared to RGC's ROE of -2.32%. Regarding short-term risk, CRON is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for CRON.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
CRON vs BHC Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while BHC trades at $6.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas BHC's P/E ratio is 1.58. In terms of profitability, CRON's ROE is +0.06%, compared to BHC's ROE of +0.89%. Regarding short-term risk, CRON is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for CRON.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
CRON vs DCPH Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas DCPH's P/E ratio is -11.58. In terms of profitability, CRON's ROE is +0.06%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, CRON is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for CRON.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
CRON vs HCM Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while HCM trades at $12.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas HCM's P/E ratio is 4.59. In terms of profitability, CRON's ROE is +0.06%, compared to HCM's ROE of +0.01%. Regarding short-term risk, CRON is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for CRON.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
CRON vs AVDL Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, CRON's ROE is +0.06%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, CRON is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for CRON.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
CRON vs EMBCV Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas EMBCV's P/E ratio is N/A. In terms of profitability, CRON's ROE is +0.06%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, CRON is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for CRON.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
CRON vs DVAX Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas DVAX's P/E ratio is -41.89. In terms of profitability, CRON's ROE is +0.06%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, CRON is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for CRON.Check DVAX's competition here
Perrigo Company plc (NYSE: PRGO)
CRON vs PRGO Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while PRGO trades at $12.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas PRGO's P/E ratio is 5.07. In terms of profitability, CRON's ROE is +0.06%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, CRON is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for CRON.Check PRGO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
CRON vs ANIP Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while ANIP trades at $75.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas ANIP's P/E ratio is 9.14. In terms of profitability, CRON's ROE is +0.06%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, CRON is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for CRON.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
CRON vs TARO Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas TARO's P/E ratio is 30.05. In terms of profitability, CRON's ROE is +0.06%, compared to TARO's ROE of +0.03%. Regarding short-term risk, CRON is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for CRON.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
CRON vs HROW Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while HROW trades at $39.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas HROW's P/E ratio is 437.33. In terms of profitability, CRON's ROE is +0.06%, compared to HROW's ROE of -1.04%. Regarding short-term risk, CRON is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for CRON.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
CRON vs PAHC Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while PAHC trades at $33.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas PAHC's P/E ratio is 11.54. In terms of profitability, CRON's ROE is +0.06%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, CRON is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for CRON.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
CRON vs ALVO Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, ALVO has a market cap of 1.4B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while ALVO trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas ALVO's P/E ratio is -11.79. In terms of profitability, CRON's ROE is +0.06%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, CRON is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for CRON.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
CRON vs ETON Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, ETON has a market cap of 1.1B. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while ETON trades at $41.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas ETON's P/E ratio is -594.00. In terms of profitability, CRON's ROE is +0.06%, compared to ETON's ROE of -0.06%. Regarding short-term risk, CRON is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for CRON.Check ETON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
CRON vs PCRX Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, PCRX has a market cap of 932.2M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while PCRX trades at $23.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas PCRX's P/E ratio is 9.12. In terms of profitability, CRON's ROE is +0.06%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, CRON is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for CRON.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
CRON vs PETQ Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas PETQ's P/E ratio is 83.73. In terms of profitability, CRON's ROE is +0.06%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, CRON is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for CRON.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
CRON vs AMPH Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, AMPH has a market cap of 881M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while AMPH trades at $19.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas AMPH's P/E ratio is 6.82. In terms of profitability, CRON's ROE is +0.06%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, CRON is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for CRON.Check AMPH's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
CRON vs COLL Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, COLL has a market cap of 842.6M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while COLL trades at $25.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas COLL's P/E ratio is 3.26. In terms of profitability, CRON's ROE is +0.06%, compared to COLL's ROE of +0.16%. Regarding short-term risk, CRON is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for CRON.Check COLL's competition here
Evotec SE (NASDAQ: EVO)
CRON vs EVO Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, EVO has a market cap of 778M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while EVO trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas EVO's P/E ratio is -3.09. In terms of profitability, CRON's ROE is +0.06%, compared to EVO's ROE of -0.24%. Regarding short-term risk, CRON is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for CRON.Check EVO's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
CRON vs IRWD Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while IRWD trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas IRWD's P/E ratio is 5.54. In terms of profitability, CRON's ROE is +0.06%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, CRON is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for CRON.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
CRON vs BDSI Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas BDSI's P/E ratio is 6.82. In terms of profitability, CRON's ROE is +0.06%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, CRON is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for CRON.Check BDSI's competition here
Evolus, Inc. (NASDAQ: EOLS)
CRON vs EOLS Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, EOLS has a market cap of 534.7M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while EOLS trades at $8.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas EOLS's P/E ratio is -25.71. In terms of profitability, CRON's ROE is +0.06%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, CRON is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for CRON.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
CRON vs AQST Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, AQST has a market cap of 530.7M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while AQST trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas AQST's P/E ratio is -6.93. In terms of profitability, CRON's ROE is +0.06%, compared to AQST's ROE of +2.44%. Regarding short-term risk, CRON is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for CRON.Check AQST's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
CRON vs TLRY Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, TLRY has a market cap of 523.4M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while TLRY trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas TLRY's P/E ratio is -4.32. In terms of profitability, CRON's ROE is +0.06%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, CRON is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for CRON.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
CRON vs CGC Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, CGC has a market cap of 432.7M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while CGC trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas CGC's P/E ratio is -0.62. In terms of profitability, CRON's ROE is +0.06%, compared to CGC's ROE of -0.33%. Regarding short-term risk, CRON is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for CRON.Check CGC's competition here
Kamada Ltd. (NASDAQ: KMDA)
CRON vs KMDA Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, KMDA has a market cap of 396.9M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while KMDA trades at $6.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas KMDA's P/E ratio is 19.66. In terms of profitability, CRON's ROE is +0.06%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, CRON is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for CRON.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
CRON vs TKNO Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, TKNO has a market cap of 396.2M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while TKNO trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas TKNO's P/E ratio is -23.84. In terms of profitability, CRON's ROE is +0.06%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, CRON is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for CRON.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
CRON vs ALIM Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas ALIM's P/E ratio is 5.28. In terms of profitability, CRON's ROE is +0.06%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, CRON is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for CRON.Check ALIM's competition here
Embecta Corp. (NASDAQ: EMBC)
CRON vs EMBC Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, EMBC has a market cap of 281.8M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while EMBC trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas EMBC's P/E ratio is 1.83. In terms of profitability, CRON's ROE is +0.06%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, CRON is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for CRON.Check EMBC's competition here
Landec Corporation (NASDAQ: LNDC)
CRON vs LNDC Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas LNDC's P/E ratio is -4.04. In terms of profitability, CRON's ROE is +0.06%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, CRON is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for CRON.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
CRON vs ACB Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, ACB has a market cap of 236.6M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while ACB trades at $3.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas ACB's P/E ratio is -7.80. In terms of profitability, CRON's ROE is +0.06%, compared to ACB's ROE of -0.21%. Regarding short-term risk, CRON is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for CRON.Check ACB's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
CRON vs ORGO Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, ORGO has a market cap of 232.9M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while ORGO trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas ORGO's P/E ratio is 60.33. In terms of profitability, CRON's ROE is +0.06%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, CRON is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for CRON.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
CRON vs TYHT Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas TYHT's P/E ratio is -1.61. In terms of profitability, CRON's ROE is +0.06%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, CRON is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for CRON.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
CRON vs SIGA Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, SIGA has a market cap of 205.8M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while SIGA trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas SIGA's P/E ratio is 10.63. In terms of profitability, CRON's ROE is +0.06%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, CRON is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for CRON.Check SIGA's competition here
Organigram Global Inc. (NASDAQ: OGI)
CRON vs OGI Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, OGI has a market cap of 181.6M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while OGI trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas OGI's P/E ratio is -4.96. In terms of profitability, CRON's ROE is +0.06%, compared to OGI's ROE of -0.07%. Regarding short-term risk, CRON is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for CRON.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
CRON vs LFCR Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, LFCR has a market cap of 178.9M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while LFCR trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas LFCR's P/E ratio is -4.46. In terms of profitability, CRON's ROE is +0.06%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, CRON is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for CRON.Check LFCR's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
CRON vs REPH Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas REPH's P/E ratio is -8.04. In terms of profitability, CRON's ROE is +0.06%, compared to REPH's ROE of -0.22%. Regarding short-term risk, CRON is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for CRON.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
CRON vs DERM Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while DERM trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas DERM's P/E ratio is -17.38. In terms of profitability, CRON's ROE is +0.06%, compared to DERM's ROE of -0.36%. Regarding short-term risk, CRON is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for CRON.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
CRON vs CRDL Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, CRDL has a market cap of 175.2M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while CRDL trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas CRDL's P/E ratio is -5.41. In terms of profitability, CRON's ROE is +0.06%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, CRON is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for CRON.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
CRON vs THTX Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas THTX's P/E ratio is -28.83. In terms of profitability, CRON's ROE is +0.06%, compared to THTX's ROE of +0.17%. Regarding short-term risk, CRON is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for CRON.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
CRON vs ASRT Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas ASRT's P/E ratio is -7.10. In terms of profitability, CRON's ROE is +0.06%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, CRON is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for CRON.Check ASRT's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
CRON vs CPIX Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while CPIX trades at $7.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas CPIX's P/E ratio is -19.90. In terms of profitability, CRON's ROE is +0.06%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, CRON is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for CRON.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
CRON vs SCTL Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas SCTL's P/E ratio is -7.86. In terms of profitability, CRON's ROE is +0.06%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, CRON is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for CRON.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
CRON vs BGM Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, BGM has a market cap of 111.9M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while BGM trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas BGM's P/E ratio is -1.01. In terms of profitability, CRON's ROE is +0.06%, compared to BGM's ROE of -0.07%. Regarding short-term risk, CRON is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for CRON.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
CRON vs PROC Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas PROC's P/E ratio is 1.53. In terms of profitability, CRON's ROE is +0.06%, compared to PROC's ROE of -2.22%. Regarding short-term risk, CRON is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for CRON.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
CRON vs OPTN Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas OPTN's P/E ratio is -4.42. In terms of profitability, CRON's ROE is +0.06%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, CRON is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for CRON.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
CRON vs ZOM Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas ZOM's P/E ratio is -1.62. In terms of profitability, CRON's ROE is +0.06%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, CRON is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for CRON.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
CRON vs GRVI Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas GRVI's P/E ratio is 26.05. In terms of profitability, CRON's ROE is +0.06%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, CRON is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for CRON.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
CRON vs ZYBT Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, ZYBT has a market cap of 73.5M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while ZYBT trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas ZYBT's P/E ratio is -7.05. In terms of profitability, CRON's ROE is +0.06%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, CRON is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for CRON.Check ZYBT's competition here
Talphera, Inc. (NASDAQ: TLPH)
CRON vs TLPH Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, TLPH has a market cap of 72.7M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while TLPH trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas TLPH's P/E ratio is -4.52. In terms of profitability, CRON's ROE is +0.06%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, CRON is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for CRON.Check TLPH's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
CRON vs ZYNE Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, CRON's ROE is +0.06%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, CRON is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for CRON.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
CRON vs SSIC Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas SSIC's P/E ratio is 11.93. In terms of profitability, CRON's ROE is +0.06%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, CRON is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for CRON.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
CRON vs VLNS Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas VLNS's P/E ratio is -1.03. In terms of profitability, CRON's ROE is +0.06%, compared to VLNS's ROE of N/A. Regarding short-term risk, CRON is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for CRON.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
CRON vs DRRX Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas DRRX's P/E ratio is -4.44. In terms of profitability, CRON's ROE is +0.06%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, CRON is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for CRON.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
CRON vs INCR Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, INCR has a market cap of 57.1M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while INCR trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas INCR's P/E ratio is -2.23. In terms of profitability, CRON's ROE is +0.06%, compared to INCR's ROE of -0.09%. Regarding short-term risk, CRON is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for CRON.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
CRON vs JUPW Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas JUPW's P/E ratio is -2.41. In terms of profitability, CRON's ROE is +0.06%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, CRON is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for CRON.Check JUPW's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
CRON vs CPHI Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, CPHI has a market cap of 44.6M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while CPHI trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas CPHI's P/E ratio is -1.72. In terms of profitability, CRON's ROE is +0.06%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, CRON is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for CRON.Check CPHI's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
CRON vs QLI Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas QLI's P/E ratio is -4.92. In terms of profitability, CRON's ROE is +0.06%, compared to QLI's ROE of -0.16%. Regarding short-term risk, CRON is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for CRON.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
CRON vs HEXO Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas HEXO's P/E ratio is -0.26. In terms of profitability, CRON's ROE is +0.06%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, CRON is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for CRON.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
CRON vs RMTI Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, RMTI has a market cap of 30.8M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while RMTI trades at $7.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas RMTI's P/E ratio is -7.42. In terms of profitability, CRON's ROE is +0.06%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, CRON is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for CRON.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
CRON vs AYTU Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while AYTU trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas AYTU's P/E ratio is -1.23. In terms of profitability, CRON's ROE is +0.06%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, CRON is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for CRON.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
CRON vs TXMD Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, TXMD has a market cap of 24.1M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while TXMD trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas TXMD's P/E ratio is 105.96. In terms of profitability, CRON's ROE is +0.06%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, CRON is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for CRON.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
CRON vs CYTH Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas CYTH's P/E ratio is -0.80. In terms of profitability, CRON's ROE is +0.06%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, CRON is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for CRON.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
CRON vs EVOK Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas EVOK's P/E ratio is -7.97. In terms of profitability, CRON's ROE is +0.06%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, CRON is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for CRON.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
CRON vs OPTH Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, OPTH has a market cap of 15.3M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while OPTH trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas OPTH's P/E ratio is -17.38. In terms of profitability, CRON's ROE is +0.06%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, CRON is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for CRON.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
CRON vs ACRX Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas ACRX's P/E ratio is -0.31. In terms of profitability, CRON's ROE is +0.06%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, CRON is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for CRON.Check ACRX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
CRON vs BFRIW Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, BFRIW has a market cap of 13.3M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, CRON's ROE is +0.06%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, CRON is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for CRON.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
CRON vs COSM Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, COSM has a market cap of 11.7M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while COSM trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas COSM's P/E ratio is -0.29. In terms of profitability, CRON's ROE is +0.06%, compared to COSM's ROE of -0.96%. Regarding short-term risk, CRON is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for CRON.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
CRON vs AGRX Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas AGRX's P/E ratio is -0.89. In terms of profitability, CRON's ROE is +0.06%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, CRON is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for CRON.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
CRON vs NLTX Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas NLTX's P/E ratio is -0.28. In terms of profitability, CRON's ROE is +0.06%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, CRON is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for CRON.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
CRON vs LCI Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas LCI's P/E ratio is -0.04. In terms of profitability, CRON's ROE is +0.06%, compared to LCI's ROE of +1.66%. Regarding short-term risk, CRON is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for CRON.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
CRON vs ADMP Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas ADMP's P/E ratio is -0.08. In terms of profitability, CRON's ROE is +0.06%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, CRON is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for CRON.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
CRON vs YCBD Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, YCBD has a market cap of 6.3M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while YCBD trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas YCBD's P/E ratio is -1.49. In terms of profitability, CRON's ROE is +0.06%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, CRON is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for CRON.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
CRON vs GELS Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, GELS has a market cap of 5.2M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while GELS trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas GELS's P/E ratio is -1.14. In terms of profitability, CRON's ROE is +0.06%, compared to GELS's ROE of -0.25%. Regarding short-term risk, CRON is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for CRON.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
CRON vs MNK Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas MNK's P/E ratio is -0.44. In terms of profitability, CRON's ROE is +0.06%, compared to MNK's ROE of -0.36%. Regarding short-term risk, CRON is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for CRON.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
CRON vs FLGC Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas FLGC's P/E ratio is -0.19. In terms of profitability, CRON's ROE is +0.06%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, CRON is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for CRON.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
CRON vs UPC Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, UPC has a market cap of 3.8M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while UPC trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas UPC's P/E ratio is -0.75. In terms of profitability, CRON's ROE is +0.06%, compared to UPC's ROE of -0.03%. Regarding short-term risk, CRON is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for CRON.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
CRON vs SBFM Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while SBFM trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas SBFM's P/E ratio is -0.20. In terms of profitability, CRON's ROE is +0.06%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, CRON is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for CRON.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
CRON vs PLXP Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas PLXP's P/E ratio is -0.22. In terms of profitability, CRON's ROE is +0.06%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, CRON is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for CRON.Check PLXP's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
CRON vs SHPH Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, SHPH has a market cap of 2.5M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while SHPH trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas SHPH's P/E ratio is -0.20. In terms of profitability, CRON's ROE is +0.06%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, CRON is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for CRON.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
CRON vs ATNX Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas ATNX's P/E ratio is -0.02. In terms of profitability, CRON's ROE is +0.06%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, CRON is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for CRON.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
CRON vs SNOA Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, SNOA has a market cap of 2.3M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while SNOA trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas SNOA's P/E ratio is -1.16. In terms of profitability, CRON's ROE is +0.06%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, CRON is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for CRON.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
CRON vs PROCW Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas PROCW's P/E ratio is N/A. In terms of profitability, CRON's ROE is +0.06%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, CRON is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for CRON.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
CRON vs RDHL Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while RDHL trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas RDHL's P/E ratio is 0.12. In terms of profitability, CRON's ROE is +0.06%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, CRON is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for CRON.Check RDHL's competition here
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
CRON vs SXTC Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, SXTC has a market cap of 1.8M. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while SXTC trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas SXTC's P/E ratio is 1.18. In terms of profitability, CRON's ROE is +0.06%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, CRON is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for CRON.Check SXTC's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
CRON vs YCBD-PA Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, CRON's ROE is +0.06%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, CRON is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for CRON.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
CRON vs CYTHW Comparison August 2026
Cronos Group Inc. (NASDAQ: CRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRON stands at 1.2B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, CRON is priced at $3.17 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRON currently has a P/E ratio of 30.10, whereas CYTHW's P/E ratio is N/A. In terms of profitability, CRON's ROE is +0.06%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, CRON is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for CRON.Check CYTHW's competition here